REGN - REGENERON PHARMACEUTICALS, INC.

766.66
-24.150   -3.150%

Share volume: 636,991
Last Updated: 03-03-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.15%

PREVIOUS CLOSE
CHG
CHG%
$790.81
-24.15
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
77%
Profitability 77%
Dept financing 34%
Liquidity 75%
Performance 89%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.92%
1 Month
-1.08%
3 Months
6.07%
6 Months
35.16%
1 Year
13.50%
2 Year
-21.06%
Key data
Stock price
$766.66
P/E Ratio 
18.01
DAY RANGE
$764.48 - $794.77
EPS 
$43.07
52 WEEK RANGE
$476.49 - $821.11
52 WEEK CHANGE
$11.57
MARKET CAP 
81.123 B
YIELD 
0.46%
SHARES OUTSTANDING 
105.720 M
DIVIDEND
$0.94
EX-DIVIDEND DATE
02-20-2026
NEXT EARNINGS DATE
07-31-2025
BETA 
0.60
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$688,544
AVERAGE 30 VOLUME 
$748,464
Company detail
CEO: Leonard S. Schleifer
Region: US
Website: regeneron.com
Employees: 11,900
IPO year: 1991
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema. Dupixent injection is used to treat atopic dermatitis and asthma in adults and pediatrics. Kevzara solution for treating rheumatoid arthritis in adults.

Recent news